Drugs / PegIFNa2a
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT00219739 | Sep 2003 → Dec 2014 | chronic myeloid leukemia | Poitiers University Hospital | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PegIFNa2a | “The pegylated form of interferon-α-2a (PegIFNa2a) in combination with imatinib has demonstrated a molecular improvement in patients with chronic-phase chronic myeloid leukemia.” PMID 24105694 ↗ Sep 2013 |
| Known as | Imatinib 400 mg + Peg-Interferon | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00219739 ↗ |